CardioBip pocket-sized ECG monitor
The problem with a heart attack – apart from the obvious of course – is that you have very little time to get to an emergency room or doctor. A medical diagnosis in the first few hours - usually by undergoing an ECG – is critical to determine the severity of the arrhythmia or ischemia (heart attack) episode. Rather than dealing with crowded emergency rooms and overstretched MD’s, this simple to use pocked-sized device can give you an ECG reading on-the-spot.
The CardioBip is a portable electrocardiogram (ECG) monitor that can generate and transmit comprehensive and accurate information. It works without any cables, wires or skin electrodes and can be used during regular daily activity or when heart attack symptoms develop.
Sick of Ads?
Join more than 500 New Atlas Plus subscribers who read our newsletter and website without ads.
It's just US$19 a year.More Information
The device contains three integrated leads that make contact with the patient’s chest. Once held against the patient’s chest, recordings will begin. The data collected by the CardioBip will provide enough information to create an accurate and immediate reconstruction of a complete 12-lead ECG. The transmitted data can also be further analyzed using the Visual3Dx array of 3-D analytical tools.
Developed by NewCardio, the CardioBip "provides sufficient information to allow accurate, immediate reconstruction of a complete 12-lead ECG from a calibrated, patient-specific transformation matrix." It can deliver information at physician-prescribed intervals of time and as the electrodes are integrated into the device, you won’t have the inconvenience of wearing skin electrodes.
The company has received a U.S patent for the device and methodology for transtelephonic transmission of ECG data for monitoring of acute cardiac conditions.
“We believe the CardioBip technology fills an important technological and diagnostic void, enabling not only rhythm diagnosis, but also detection of ischemic ECG changes and precise reconstruction of a trial activity,” said Branislav Vajdic, Ph.D, chief executive officer of NewCardio “At present there is no convenient and reliable method for remote monitoring and detection of either ischemic events or derangements of atrial electrical activity, but this patent and the two recently completed validation studies indicate that the CardioBip may potentially fill this need.”
No news yet on when this product will become available, but given the number of people who suffer from heart attacks each year, let’s hope it’s sooner rather than later.